TORONTO, July 8 /CNW/ - Patheon (TSX:PTI), a global provider of drug
development and manufacturing services to the international pharmaceutical
industry, is pleased to have been selected by SK Life Science, Inc. (formerly
known as SK Bio-Pharmaceuticals), the US-based subsidiary of Korean SK
Holdings as their development services partner for two additional innovative
Central Nervous System (CNS) drug candidates.
"We are very pleased to have been selected by SK Life Science to develop
these important new drug candidates, and we look forward to continuing to
provide them with exceptional service on their development projects," said Wes
Wheeler, President and Chief Executive Officer of Patheon Inc. "This agreement
to develop SK Life Science's two innovative candidates for the treatment of
CNS disorders expands upon our existing relationship with the Company, having
recently completed phase I development and clinical materials manufacturing
for their next generation pain drug candidate. This agreement also
demonstrates our continued commitment to provide best in class development and
manufacturing services to an expanding global customer base, including the
growing Korean pharmaceutical industry."
"Patheon produced quality clinical materials for the pain drug project
within our timelines. As a result we were very comfortable with awarding
Patheon these two additional key projects," said Dr. S. James Lee, Vice
President Pharmaceutical Development of SK Life Science.
Patheon will provide formulation and analytical development services as
well as clinical supplies for one of the CNS candidates in multiple dosage
forms for SK Life Science's advanced clinical studies. In addition, Patheon
will provide development and clinical materials manufacturing services for
another CNS candidate in Phase I clinical trials. Both of these candidates are
being developed for one of the largest pharmaceutical therapeutic categories.
The global CNS market is expected to grow to $63.9 billion by 2010, according
to Urch Publishing.
ABOUT SK Life Science, Inc.
Through its subsidiary SK Life Science, Inc. (http://pharma.sk.com), SK
Holdings, Co., Ltd., the second largest conglomerate and the leading energy
and chemical company in Korea, has been engaged in the innovative discovery
and development of novel therapeutic compounds in the field of neuroscience in
order to treat CNS disorders including epilepsy, depression, anxiety,
schizophrenia, Parkinson's disease, and other neurodegenerative disorders. In
addition to the CNS area of research, SK Life Science is working on the
discovery and development of novel therapeutic compounds for the treatment of
Patheon Inc. (TSX:PTI; www.patheon.com) is a leading global provider of
contract development and manufacturing services to the global pharmaceutical
industry. Patheon prides itself in providing the highest quality products and
services to more than 300 of the world's leading pharmaceutical and
biotechnology companies. Patheon's services range from preclinical development
through commercial manufacturing of a full array of dosage forms including
parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative
technologies including single-use disposables, Liquid-Filled Hard Capsules and
a variety of modified release technologies.
Patheon's comprehensive range of fully integrated Pharmaceutical
Development Services includes pre-formulation, formulation, analytical
development, clinical manufacturing, scale-up and commercialization. Patheon
can take customers direct to clinic with global clinical packaging and
distribution services and Patheon's Quick to Clinic(TM) programs can
accelerate early phase development project to clinical trials while minimizing
the consumption of valuable API.
Patheon's integrated development and manufacturing network of 11
facilities, and 6 development centers across North America and Europe, strives
to ensure that customer products can be launched with confidence anywhere in
Caution Concerning Forward-Looking Statements
This news release may contain forward-looking statements which reflect
management's expectations regarding the Company's future growth of operations,
performance (both operational and financial) and business prospects and
opportunities. These statements are made in the context of the risks and
uncertainties that are outlined in the Company's public documents, which can
be accessed on our website at www.patheon.com or on SEDAR at www.sedar.com.
For further information:
For further information: Mr. Wes Wheeler, President & Chief Executive
Officer, Tel: (905) 812-2112, Email: firstname.lastname@example.org; Mr. Terry Novak,
President of North America, Chief Marketing Officer, Tel: (862) 207-1262,
Email: email@example.com; Ms. Jean Treadwell, Investor Relations, Tel:
(905) 816-8344, Email: firstname.lastname@example.org